Home / Deep Research / Infantile Parkinsonism-Dystonia

Infantile Parkinsonism-Dystonia

1. Disease Information (Overview)

2026-06-04
Falcon MONDO:0013150 Model: Edison Scientific Literature 34 citations

1. Disease Information (Overview)

DTDS as the prototypic infantile parkinsonism–dystonia: A 2023 review explicitly states: “Infantile parkinsonism-dystonia due to dopamine transporter deficiency syndrome (DTDS) is an ultrarare childhood movement disorder caused by biallelic loss-of-function mutations in the SLC6A3 gene.” (Published Jun 2023; https://doi.org/10.3390/cells12131737). (ng2023dopaminetransporterdeficiency pages 1-2)

Newly described cause (DRD1): A 2023 report describes a proband with “severe infantile parkinsonism-dystonia…frequent oculogyric crises, dysautonomia and global neurodevelopmental impairment,” and identifies a homozygous loss-of-function DRD1 variant. (Published Mar 2023; https://doi.org/10.3390/cells12071046). (reid2023lossoffunctionvariantsin pages 1-2)

SLC18A2/PKDYS2 overlap: A 2024 PKDYS2 case report describes infantile-onset dystonia-parkinsonism due to SLC18A2 with oculogyric crises, hypotonia, and severe disability, underscoring overlap with the infantile parkinsonism-dystonia clinical space. (Published Apr 2024; https://doi.org/10.1155/2024/4767647). (kaasalainen2024novelslc18a2variant pages 1-2, kaasalainen2024novelslc18a2variant pages 2-3)

2. Etiology

2.1 Disease causal factors (primary)

Genetic (Mendelian) etiologies supported by retrieved evidence: 1) SLC6A3 (DAT) loss of function → DTDS (autosomal recessive; also atypical forms may include dominant-negative mechanisms per review text) (ng2023dopaminetransporterdeficiency pages 1-2, thalib2025acomparativeexploration pages 3-4) 2) DRD1 loss of function (recessive, currently single-family evidence in 2023 report) (reid2023lossoffunctionvariantsin pages 1-2) 3) SLC18A2 (VMAT2) loss of function → PKDYS2/parkinsonism-dystonia-2 (autosomal recessive) (kaasalainen2024novelslc18a2variant pages 1-2, almutair2026casereporttwo pages 2-4)

2.2 Risk factors

  • Genetic risk factors: biallelic pathogenic variants in the causal genes above; consanguinity is highlighted for the DRD1 case (consanguineous parents) and in PKDYS2 sibling cases. (reid2023lossoffunctionvariantsin pages 6-8, almutair2026casereporttwo pages 2-4)
  • Environmental risk factors: No specific environmental risk factors were identified in the retrieved evidence for infantile parkinsonism–dystonia as a Mendelian disorder.

2.3 Protective factors / gene–environment interactions

No protective factors or gene–environment interactions were identified in the retrieved evidence.

3. Phenotypes (Clinical Spectrum)

3.1 Core phenotype domains (DTDS-focused)

A 2023 DTDS review describes early-onset nonspecific symptoms evolving to mixed hyper/hypokinetic movement disorder and parkinsonism-dystonia: - Infantile onset features: irritability, feeding difficulties, hypotonia, delayed motor development (ng2023dopaminetransporterdeficiency pages 2-3) - Hyperkinetic movements: chorea, dystonia, ballismus, orolingual dyskinesia (ng2023dopaminetransporterdeficiency pages 2-3) - Progression to parkinsonism-dystonia: dystonic posturing, bradykinesia, tremor, rigidity, akinesia (ng2023dopaminetransporterdeficiency pages 2-3) - Episodic crises: status dystonicus; eye movement disorders including oculogyric crisis (ng2023dopaminetransporterdeficiency pages 2-3)

Age of onset: For DTDS, a comparative review notes typical presentation “within the first 6 months of life.” (thalib2025acomparativeexploration pages 3-4)

3.2 Phenotypes in DRD1-associated infantile parkinsonism-dystonia

The 2023 DRD1 report provides a granular infantile-onset phenotype including: - Global developmental delay with failure of gross motor and vocal milestones (e.g., never sitting/rolling/babbling) (reid2023lossoffunctionvariantsin pages 6-8) - Recurrent generalized dystonia with oculogyric crises (reid2023lossoffunctionvariantsin pages 6-8) - Feeding impairment requiring enteral nutrition; gastrointestinal dysmotility symptoms (reflux/constipation) (reid2023lossoffunctionvariantsin pages 6-8) - Dysautonomia/autonomic-type features: excessive sweating and chronic nasal congestion described (reid2023lossoffunctionvariantsin pages 6-8)

3.3 Phenotypes in SLC18A2 (PKDYS2)

The 2024 PKDYS2 report describes: - Early abnormalities in infancy (first noted at 2 months in the case report) with oculogyric crises, hypotonia, delayed psychomotor development and recurrent generalized dystonic episodes (kaasalainen2024novelslc18a2variant pages 1-2) - Severe functional disability by later childhood with dependence for all activities (kaasalainen2024novelslc18a2variant pages 2-3)

3.4 Suggested HPO terms (based on reported clinical features)

Examples (non-exhaustive; align to the evidence above): - Dystonia (HP:0001332) (ng2023dopaminetransporterdeficiency pages 2-3, reid2023lossoffunctionvariantsin pages 6-8) - Parkinsonism (HP:0001300) (ng2023dopaminetransporterdeficiency pages 2-3) - Bradykinesia (HP:0002067) (ng2023dopaminetransporterdeficiency pages 2-3) - Rigidity (HP:0002063) (ng2023dopaminetransporterdeficiency pages 2-3) - Oculogyric crisis (HP:0002179) (ng2023dopaminetransporterdeficiency pages 2-3, reid2023lossoffunctionvariantsin pages 6-8, kaasalainen2024novelslc18a2variant pages 1-2) - Hypotonia (HP:0001252) (ng2023dopaminetransporterdeficiency pages 2-3, reid2023lossoffunctionvariantsin pages 6-8, kaasalainen2024novelslc18a2variant pages 1-2) - Global developmental delay (HP:0001263) (reid2023lossoffunctionvariantsin pages 1-2, reid2023lossoffunctionvariantsin pages 6-8, kaasalainen2024novelslc18a2variant pages 2-3) - Feeding difficulties (HP:0011968) / Dysphagia (HP:0002015) (ng2023dopaminetransporterdeficiency pages 2-3, reid2023lossoffunctionvariantsin pages 6-8, kaasalainen2024novelslc18a2variant pages 2-3) - Autonomic dysfunction (HP:0002311) / Hyperhidrosis (HP:0000975) (reid2023lossoffunctionvariantsin pages 1-2, reid2023lossoffunctionvariantsin pages 6-8)

3.5 Quality of life impact

The DTDS review notes high care burden (e.g., many require gastrostomy feeding) and severe disability, implying profound quality-of-life impairment for patients and caregivers. (ng2023dopaminetransporterdeficiency pages 2-3)

3.6 Differential diagnosis (high-level, evidence-supported)

DTDS/infantile parkinsonism-dystonia can phenotypically resemble other monoamine neurotransmitter disorders (including disorders of dopamine synthesis/metabolism and vesicular transport). The DRD1 case explicitly notes similarity to monoamine disorders such as AADC deficiency. (reid2023lossoffunctionvariantsin pages 10-12)

4. Genetic / Molecular Information

4.1 Causal genes and inheritance (supported here)

4.2 Pathogenic variant classes and functional consequences

SLC6A3 (reviewed in 2023): Pathogenic variants include protein-truncating variants (nonsense, splice-site, deletions) and missense substitutions, with functional consequences including reduced transporter activity, impaired dopamine binding, reduced cell-surface expression, and impaired glycosylation. (ng2023dopaminetransporterdeficiency pages 1-2)

DRD1 p.T37K (2023): In vitro and modeling indicate loss of receptor function (reduced cAMP response; reduced ligand binding). (reid2023lossoffunctionvariantsin pages 1-2, reid2023lossoffunctionvariantsin pages 10-12)

SLC18A2 PKDYS2 (2024): frameshift variant consistent with loss-of-function mechanism; clinical presentation consistent with severe infantile dystonia-parkinsonism. (kaasalainen2024novelslc18a2variant pages 1-2)

4.3 Genotype–phenotype / case counts (DTDS)

The DTDS review summarizes published case numbers: “thirty-one DTDS patients reported in the literature,” plus “a further unpublished twenty patients reported to our centre.” (ng2023dopaminetransporterdeficiency pages 2-3)

5. Environmental Information

No disease-relevant environmental or lifestyle contributors were identified in the retrieved evidence; the disorders discussed are primarily genetic neurotransmitter/transportopathies.

6. Mechanism / Pathophysiology

6.1 DTDS (SLC6A3) mechanistic chain (integrated from multiple evidence sources)

Upstream trigger: loss-of-function in DAT (SLC6A3) reduces dopamine reuptake capacity (ng2023dopaminetransporterdeficiency pages 1-2)

Biochemical consequence (CSF): elevated dopamine catabolism marker HVA with normal 5-HIAA; elevated HVA:5-HIAA ratio (often 5.0–13.0; normal 1.0–4.0). (ng2023dopaminetransporterdeficiency pages 2-3)

Cellular consequences: patient iPSC-derived midbrain dopaminergic neurons show impaired DAT activity with dopamine toxicity, oxidative/carbonyl stress, inflammation-associated apoptosis, and dopaminergic neurodegeneration. (ng2021genetherapyrestores pages 4-6, ng2021genetherapyrestores pages 1-3, ng2021genetherapyrestores pages 17-25)

Circuit/organ consequences: DTDS knockout mice exhibit tremor, bradykinesia, and premature death; gene replacement rescues motor phenotype and neurodegeneration in vivo, supporting a causal link between transporter loss and progressive neurological dysfunction. (ng2021genetherapyrestores pages 1-3, ng2021genetherapyrestores pages 6-8)

6.2 DAT variant mechanism (example: R445C) and “pharmacological rescue” concept

A DTDS-associated DAT substitution R445C disrupts a conserved intracellular gating interaction network, producing compromised transporter function and reduced expression/trafficking; Drosophila expressing hDAT R445C show motor coordination defects, and dietary chloroquine (lysosomal inhibitor) improves a flight-initiation phenotype, consistent with partially restoring DAT maturation/availability. (aguilar2021psychomotorimpairmentsand pages 1-2, aguilar2021psychomotorimpairmentsand pages 14-16)

6.3 DRD1 mechanism

The DRD1 p.T37K variant is predicted and shown to reduce ligand binding and downstream receptor signaling (cAMP response), yielding an infantile parkinsonism–dystonia phenotype despite unexpectedly normal CSF neurotransmitter measures, suggesting postsynaptic dopamine signaling failure can phenocopy presynaptic dopamine deficiency syndromes. (reid2023lossoffunctionvariantsin pages 1-2, reid2023lossoffunctionvariantsin pages 10-12)

6.4 Suggested GO biological process terms (examples)

6.5 Suggested CL (cell types) and UBERON (anatomy) terms

Cell types (CL): - Midbrain dopaminergic neuron (CL:2000091) (supported by iPSC mDA neuron modeling) (ng2021genetherapyrestores pages 1-3) - Striatal medium spiny neuron (CL:0000540) (electrophysiological/circuit consequences discussed in DTDS models) (ng2021genetherapyrestores pages 8-9)

Anatomy (UBERON): - Substantia nigra (UBERON:0002038) and striatum (UBERON:0002435), targeted/affected in DTDS gene therapy studies (ng2021genetherapyrestores pages 6-8)

7. Anatomical Structures Affected

Evidence from DTDS modeling and therapeutic targeting implicates the nigrostriatal dopaminergic system, including substantia nigra and striatum, as critical affected/targeted structures (demonstrated by targeted AAV2.SLC6A3 delivery to substantia nigra with anterograde transport to striatum and motor rescue). (ng2021genetherapyrestores pages 8-9, ng2021genetherapyrestores pages 6-8)

8. Temporal Development

9. Inheritance and Population

9.1 Inheritance patterns

9.2 Epidemiology / frequency

DTDS is described as ultrarare; a 2023 review summarizes a published case count (~31 in the literature) plus additional unpublished cases known to a specialist center, and reports deaths in childhood with mean reported age of death 10.4 years (see Prognosis below). (ng2023dopaminetransporterdeficiency pages 2-3)

Robust prevalence/incidence rates were not present in the retrieved evidence.

10. Diagnostics

10.1 Key biochemical and imaging findings (DTDS)

10.2 Genetic testing approach

A comparative review states that DTDS diagnosis is confirmed by pathogenic SLC6A3 variants and that the “diagnostic test of choice is a genetic panel such as whole exome sequencing (WES).” (thalib2025acomparativeexploration pages 3-4)

Recent real-world implementation examples: - DRD1 case used trio WGS (30×) and Sanger segregation confirmation. (reid2023lossoffunctionvariantsin pages 2-4) - PKDYS2 case used WES to identify a homozygous SLC18A2 frameshift variant. (kaasalainen2024novelslc18a2variant pages 1-2)

10.3 Differential diagnosis considerations

IPD/DTDS can be confused with other early-onset neurogenetic or neurotransmitter disorders; DRD1 report emphasizes phenotypic similarity to monoamine disorders (e.g., AADC deficiency). (reid2023lossoffunctionvariantsin pages 10-12)

11. Outcome / Prognosis

A 2023 DTDS review reports severe outcomes including childhood death: “eight children have died… mean age of death of 10.4 years.” (ng2023dopaminetransporterdeficiency pages 2-3)

Longitudinal functional outcomes in PKDYS2 include severe disability with need for assistance for all activities (case report by age 9). (kaasalainen2024novelslc18a2variant pages 2-3)

12. Treatment

12.1 Symptomatic pharmacotherapy (DTDS)

The 2023 DTDS review states there is “limited response to standard pharmacotherapies,” with symptomatic approaches including: - tetrabenazine and benzodiazepines for chorea/dyskinesia (ng2023dopaminetransporterdeficiency pages 2-3) - dopamine agonists (e.g., pramipexole, ropinirole) (ng2023dopaminetransporterdeficiency pages 2-3) - gabapentin for stiffness in some cases (ng2023dopaminetransporterdeficiency pages 2-3) - levodopa: “limited or no response to levodopa treatment.” (ng2023dopaminetransporterdeficiency pages 2-3)

MAXO suggestions (examples): - Dopamine agonist therapy (MAXO:0001027) - Levodopa therapy (MAXO:0000746) - Tetrabenazine therapy / monoamine depletion therapy (MAXO term may vary by ontology version; treat as “vesicular monoamine transporter inhibitor therapy”) - Benzodiazepine therapy (MAXO:0000558)

12.2 Treatment response in DRD1 infantile parkinsonism-dystonia

12.3 Treatment response in PKDYS2 (SLC18A2)

The 2024 PKDYS2 case report describes trials including valproate, levodopa-carbidopa, pramipexole, amantadine, methylphenidate with variable/limited benefit and frequent adverse effects; it also notes that levodopa in PKDYS2 “almost always worsens” in prior reports, with dopamine agonists variably beneficial. (kaasalainen2024novelslc18a2variant pages 1-2, kaasalainen2024novelslc18a2variant pages 2-3)

12.4 Advanced therapeutics and experimental approaches (DTDS)

Gene therapy as a major translational direction: - A 2021 Science Translational Medicine study demonstrates that viral gene transfer of wild-type SLC6A3 restores DAT activity and prevents neurodegeneration in patient-derived iPSC midbrain dopaminergic neurons, and that AAV delivery improves motor phenotype, lifespan, and neuronal survival in DTDS mouse models, with dose-related off-target toxicity at high doses and improved safety with targeted midbrain AAV2.SLC6A3 delivery. (Published May 2021; https://doi.org/10.1126/scitranslmed.aaw1564). (ng2021genetherapyrestores pages 1-3, ng2021genetherapyrestores pages 6-8)

Expert/authoritative perspective on translation (2023): A 2023 Movement Disorders review frames a regulatory and translational landscape for dopamine gene therapies, noting approval of Upstaza (AADC deficiency) as an “important land-mark” while emphasizing that “numerous challenges remain,” including defining the “optimal therapeutic window,” durability of effect, and improved brain targeting—issues directly relevant to DTDS translation. (Published May 2023; https://doi.org/10.1002/mds.29416). (ng2023genetherapyfor pages 1-2)

13. Prevention

No primary prevention is applicable for these Mendelian disorders beyond genetic counseling and reproductive options.

Secondary/tertiary prevention concept: early molecular diagnosis (WES/WGS) may reduce diagnostic delay and avoid ineffective treatments; emphasized in PKDYS2 sibling case conclusions and DTDS diagnostic summaries. (almutair2026casereporttwo pages 2-4, thalib2025acomparativeexploration pages 3-4)

14. Other Species / Natural Disease

No naturally occurring (non-experimental) animal disease analogs were identified in the retrieved evidence.

15. Model Organisms

Evidence-supported models include:

1) Patient-derived iPSC midbrain dopaminergic neurons (DTDS/SLC6A3): show impaired DAT activity, apoptotic neurodegeneration, TNFα-mediated inflammation, and dopamine toxicity; enable testing of pharmacochaperones and viral gene replacement. (ng2021genetherapyrestores pages 1-3, ng2021genetherapyrestores pages 17-25)

2) DAT knockout mouse (DTDS/SLC6A3): recapitulates tremor, bradykinesia, and premature death; used for AAV2.SLC6A3 dose-ranging, motor rescue, survival outcomes, and targeting strategy development. (ng2021genetherapyrestores pages 1-3, ng2021genetherapyrestores pages 8-9)

3) Drosophila DAT variant model (hDAT R445C): demonstrates impaired DAT activity, dopamine dysfunction, motor coordination phenotypes (including flight coordination), and pharmacologic rescue by chloroquine via increased DAT maturation/expression. (aguilar2021psychomotorimpairmentsand pages 1-2, aguilar2021psychomotorimpairmentsand pages 14-16)

Recent developments and latest research (prioritizing 2023–2024)

1) New disease gene for infantile parkinsonism-dystonia (DRD1): 2023 Cells report nominates DRD1 as a new disease-associated gene with recessive loss-of-function and severe infantile phenotype, with normal CSF neurotransmitter analysis and poor response to dopaminergic therapy. (Mar 2023; https://doi.org/10.3390/cells12071046). (reid2023lossoffunctionvariantsin pages 1-2, reid2023lossoffunctionvariantsin pages 6-8)

2) DTDS precision medicine framing (2023 Cells review): summarizes expanding phenotype, typical diagnostic findings (CSF ratio, DaTScan), case counts, limited levodopa response, and highlights pharmacochaperones and gene therapy in development. (Jun 2023; https://doi.org/10.3390/cells12131737). (ng2023dopaminetransporterdeficiency pages 2-3)

3) SLC18A2 PKDYS2 case expansion (2024): reports a novel frameshift variant diagnosed via WES with extensive medication trials documenting limited or transient responses and adverse effects. (Apr 2024; https://doi.org/10.1155/2024/4767647). (kaasalainen2024novelslc18a2variant pages 1-2, kaasalainen2024novelslc18a2variant pages 2-3)

4) Gene therapy translation analysis (2023 Movement Disorders): emphasizes therapeutic window, targeting specificity, and durability as key unresolved questions across dopamine gene therapies (relevant to DTDS). (May 2023; https://doi.org/10.1002/mds.29416). (ng2023genetherapyfor pages 1-2, ng2023genetherapyfor pages 9-11)

Summary Table (evidence-backed)

The following table consolidates key Mendelian causes and distinguishing diagnostic/treatment features captured in the retrieved evidence.

Table (click to expand)
Disease label used in papers Causal gene Inheritance Key distinguishing clinical features Key diagnostic tests/findings Typical treatment response notes Key recent references
Dopamine transporter deficiency syndrome (DTDS); infantile parkinsonism-dystonia SLC6A3 Usually autosomal recessive due to biallelic loss-of-function variants; review also notes heterozygous dominant-negative SLC6A3 variants in atypical DTDS (thalib2025acomparativeexploration pages 3-4, ng2023dopaminetransporterdeficiency pages 1-2) Infantile onset, often within first 6 months; irritability, feeding difficulties, hypotonia, delayed motor milestones; hyperkinetic movements (chorea, dystonia, ballismus, orolingual dyskinesia) progressing to parkinsonism-dystonia with bradykinesia, tremor, rigidity, akinesia; oculogyric crises/status dystonicus; dysautonomia and severe disability in many cases (ng2023dopaminetransporterdeficiency pages 2-3, thalib2025acomparativeexploration pages 1-3) CSF: raised HVA with normal 5-HIAA; HVA:5-HIAA ratio typically 5.0–13.0 (normal 1.0–4.0), or practical cutoff >4; DaTScan/SPECT: absent or markedly reduced basal nuclei uptake; MRI may be normal or show mild delayed myelination/white-matter abnormalities/prominent frontotemporal spaces; diagnosis confirmed by WES/gene panel/WGS showing pathogenic SLC6A3 variants (ng2023dopaminetransporterdeficiency pages 2-3, thalib2025acomparativeexploration pages 3-4) Limited response to standard pharmacotherapy; tetrabenazine and benzodiazepines used for chorea/dyskinesia; dopamine agonists such as pramipexole/ropinirole sometimes used; gabapentin may help stiffness; limited or no response to levodopa; DBS and intrathecal baclofen reported with limited benefit; preclinical gene therapy and pharmacochaperone approaches under development (ng2023dopaminetransporterdeficiency pages 2-3, ng2021genetherapyrestores pages 1-3, ng2023genetherapyfor pages 1-2) Ng et al., 2023, https://doi.org/10.3390/cells12131737; Ng et al., 2023, https://doi.org/10.1002/mds.29416 (ng2023dopaminetransporterdeficiency pages 2-3, ng2023genetherapyfor pages 1-2)
Infantile parkinsonism-dystonia due to DRD1 loss of function DRD1 Autosomal recessive in reported case (homozygous variant) (reid2023lossoffunctionvariantsin pages 12-13, reid2023lossoffunctionvariantsin pages 1-2) Severe infantile parkinsonism-dystonia with frequent oculogyric crises, dysautonomia, global neurodevelopmental impairment; paucity of spontaneous movement, hypomimia, truncal hypotonia with variable limb tone, prolonged generalized dystonia, feeding impairment, reflux, constipation, sweating, chronic nasal congestion; failed to sit/roll/babble (reid2023lossoffunctionvariantsin pages 1-2, reid2023lossoffunctionvariantsin pages 6-8) Trio WGS identified homozygous DRD1 c.110C>A (p.T37K), absent from gnomAD; CSF neurotransmitters/AADC activity were normal, with slight increase in HVA:5-HIAA noted in supplementary data; MRI referenced in supplementary materials; functional assays showed markedly reduced D1 receptor signaling/ligand binding (reid2023lossoffunctionvariantsin pages 12-13, reid2023lossoffunctionvariantsin pages 1-2, reid2023lossoffunctionvariantsin pages 6-8, reid2023lossoffunctionvariantsin pages 8-10) No clinical response to levodopa up to 10 mg/kg/day; numerous D1 agonists failed to rescue the cellular defect, matching lack of dopaminergic benefit clinically; modest benefit from some tone-modifying agents and transdermal clonidine reported (reid2023lossoffunctionvariantsin pages 12-13, reid2023lossoffunctionvariantsin pages 6-8, reid2023lossoffunctionvariantsin pages 10-12) Reid et al., 2023, https://doi.org/10.3390/cells12071046 (reid2023lossoffunctionvariantsin pages 1-2, reid2023lossoffunctionvariantsin pages 12-13)
Infantile dystonia-parkinsonism type 2 (PKDYS2); parkinsonism-dystonia-2; brain dopamine-serotonin vesicular transport disease SLC18A2 Autosomal recessive (reported homozygous variants) (kaasalainen2024novelslc18a2variant pages 1-2, almutair2026casereporttwo pages 2-4) Onset in early infancy; global developmental delay, generalized hypotonia, hyperkinetic movements/dystonia, parkinsonism, oculogyric crises, temperature instability/autonomic features, severe speech and motor impairment, feeding/swallowing problems; many remain nonambulatory and dependent for all activities (kaasalainen2024novelslc18a2variant pages 1-2, kaasalainen2024novelslc18a2variant pages 2-3, kaasalainen2024novelslc18a2variant pages 3-4, almutair2026casereporttwo pages 2-4) WES identified homozygous SLC18A2 variants including frameshift c.1107dup p.(Val370Serfs*91) and splice-site c.1122+2T>C; EEG may show no epileptiform activity; brain MRI can be unremarkable/normal; CSF testing was planned but not available in one 2026 report (kaasalainen2024novelslc18a2variant pages 1-2, kaasalainen2024novelslc18a2variant pages 2-3, almutair2026casereporttwo pages 2-4) Levodopa often ineffective or may worsen symptoms; pramipexole can give partial/initial benefit (head support, swallowing, breathing, reduced dystonic episodes) but adverse effects may limit use; valproate mild or unclear benefit; amantadine no clear benefit; methylphenidate may transiently improve alertness/head support but can worsen dystonia/side effects (kaasalainen2024novelslc18a2variant pages 1-2, kaasalainen2024novelslc18a2variant pages 2-3, almutair2026casereporttwo pages 2-4) Kaasalainen et al., 2024, https://doi.org/10.1155/2024/4767647 (kaasalainen2024novelslc18a2variant pages 1-2, kaasalainen2024novelslc18a2variant pages 2-3)

Table: This table summarizes Mendelian causes discussed in the retrieved evidence for infantile parkinsonism-dystonia and related infantile dystonia-parkinsonism disorders. It compares genes, inheritance, distinguishing clinical features, diagnostic findings, treatment response patterns, and recent references supported by the available evidence snippets.

Limitations of this report (due to available tool evidence)

  • Several required identifiers (MONDO, Orphanet, MeSH, ICD codes) and population-level prevalence/incidence were not present in the retrieved full-text snippets; they are therefore not reported to avoid uncited or inaccurate assertions.
  • Many classic DTDS primary series (e.g., earliest cohorts) are referenced within reviews but were not directly available as full text in the retrieved evidence set for direct PMID-quoting.

References

  1. (ng2023dopaminetransporterdeficiency pages 2-3): Joanne Ng, Serena Barral, Simon N. Waddington, and Manju A. Kurian. Dopamine transporter deficiency syndrome (dtds): expanding the clinical phenotype and precision medicine approaches. Cells, 12:1737, Jun 2023. URL: https://doi.org/10.3390/cells12131737, doi:10.3390/cells12131737. This article has 27 citations.

  2. (ng2023dopaminetransporterdeficiency pages 1-2): Joanne Ng, Serena Barral, Simon N. Waddington, and Manju A. Kurian. Dopamine transporter deficiency syndrome (dtds): expanding the clinical phenotype and precision medicine approaches. Cells, 12:1737, Jun 2023. URL: https://doi.org/10.3390/cells12131737, doi:10.3390/cells12131737. This article has 27 citations.

  3. (reid2023lossoffunctionvariantsin pages 1-2): Genomics England Research, Kimberley M Reid, D. Steel, Sanjana Nair, S. Bhate, L. Biassoni, S. Sudhakar, M. Heys, Elizabeth A Burke, E. Kamsteeg, Genomics England, Research Consortium, B. Hameed, M. Zech, N. Mencacci, Katy Barwick, M. Topf, and M. Kurian. Loss-of-function variants in drd1 in infantile parkinsonism-dystonia. Cells, 12:1046, Mar 2023. URL: https://doi.org/10.3390/cells12071046, doi:10.3390/cells12071046. This article has 15 citations.

  4. (kaasalainen2024novelslc18a2variant pages 1-2): Sakari Kaasalainen, Harri Arikka, Mika H. Martikainen, and Valtteri Kaasinen. Novel slc18a2 variant in infantile dystonia-parkinsonism type 2. Case Reports in Neurological Medicine, Apr 2024. URL: https://doi.org/10.1155/2024/4767647, doi:10.1155/2024/4767647. This article has 3 citations and is from a peer-reviewed journal.

  5. (almutair2026casereporttwo pages 2-4): Meshal Almutair and Wejdan S. Hakami. Case report: two siblings with a novel homozygous slc18a2 variant causing parkinsonism-dystonia-2: a case series from saudi arabia. Frontiers in Genetics, May 2026. URL: https://doi.org/10.3389/fgene.2026.1812336, doi:10.3389/fgene.2026.1812336. This article has 0 citations and is from a peer-reviewed journal.

  6. (ng2021genetherapyrestores pages 1-3): Joanne Ng, Serena Barral, Carmen De La Fuente Barrigon, Gabriele Lignani, Fatma A. Erdem, Rebecca Wallings, Riccardo Privolizzi, Giada Rossignoli, Haya Alrashidi, Sonja Heasman, Esther Meyer, Adeline Ngoh, Simon Pope, Rajvinder Karda, Dany Perocheau, Julien Baruteau, Natalie Suff, Juan Antinao Diaz, Stephanie Schorge, Jane Vowles, Lucy R. Marshall, Sally A. Cowley, Sonja Sucic, Michael Freissmuth, John R. Counsell, Richard Wade-Martins, Simon J. R. Heales, Ahad A. Rahim, Maximilien Bencze, Simon N. Waddington, and Manju A. Kurian. Gene therapy restores dopamine transporter expression and ameliorates pathology in ipsc and mouse models of infantile parkinsonism. Science Translational Medicine, May 2021. URL: https://doi.org/10.1126/scitranslmed.aaw1564, doi:10.1126/scitranslmed.aaw1564. This article has 59 citations and is from a highest quality peer-reviewed journal.

  7. (aguilar2021psychomotorimpairmentsand pages 1-2): Jenny I Aguilar, Mary Hongying Cheng, Josep Font, Alexandra C Schwartz, Kaitlyn Ledwitch, Amanda Duran, Samuel J Mabry, Andrea N Belovich, Yanqi Zhu, Angela M Carter, Lei Shi, Manju A Kurian, Cristina Fenollar-Ferrer, Jens Meiler, Renae Monique Ryan, Hassane S Mchaourab, Ivet Bahar, Heinrich JG Matthies, and Aurelio Galli. Psychomotor impairments and therapeutic implications revealed by a mutation associated with infantile parkinsonism-dystonia. May 2021. URL: https://doi.org/10.7554/elife.68039, doi:10.7554/elife.68039. This article has 24 citations and is from a domain leading peer-reviewed journal.

  8. (kaasalainen2024novelslc18a2variant pages 2-3): Sakari Kaasalainen, Harri Arikka, Mika H. Martikainen, and Valtteri Kaasinen. Novel slc18a2 variant in infantile dystonia-parkinsonism type 2. Case Reports in Neurological Medicine, Apr 2024. URL: https://doi.org/10.1155/2024/4767647, doi:10.1155/2024/4767647. This article has 3 citations and is from a peer-reviewed journal.

  9. (thalib2025acomparativeexploration pages 3-4): Husna Irfan Thalib, Rand Redwan Al Sari, Syeda Sobiah Imad, Sariya Khan, Shyma Haidar, Bayan Mohammed Khair Al Zoabi, Sahar Hamed Fadda, Samratul Fuadah, Hassan Abu Alwan, and Abdullah Alghobaishi. A comparative exploration of monoamine neurotransmitter transport disorders: mechanisms, clinical manifestations, and therapeutic approaches. Journal of Medicine and Life, 18:188-195, Mar 2025. URL: https://doi.org/10.25122/jml-2024-0398, doi:10.25122/jml-2024-0398. This article has 3 citations.

  10. (reid2023lossoffunctionvariantsin pages 6-8): Genomics England Research, Kimberley M Reid, D. Steel, Sanjana Nair, S. Bhate, L. Biassoni, S. Sudhakar, M. Heys, Elizabeth A Burke, E. Kamsteeg, Genomics England, Research Consortium, B. Hameed, M. Zech, N. Mencacci, Katy Barwick, M. Topf, and M. Kurian. Loss-of-function variants in drd1 in infantile parkinsonism-dystonia. Cells, 12:1046, Mar 2023. URL: https://doi.org/10.3390/cells12071046, doi:10.3390/cells12071046. This article has 15 citations.

  11. (reid2023lossoffunctionvariantsin pages 10-12): Genomics England Research, Kimberley M Reid, D. Steel, Sanjana Nair, S. Bhate, L. Biassoni, S. Sudhakar, M. Heys, Elizabeth A Burke, E. Kamsteeg, Genomics England, Research Consortium, B. Hameed, M. Zech, N. Mencacci, Katy Barwick, M. Topf, and M. Kurian. Loss-of-function variants in drd1 in infantile parkinsonism-dystonia. Cells, 12:1046, Mar 2023. URL: https://doi.org/10.3390/cells12071046, doi:10.3390/cells12071046. This article has 15 citations.

  12. (ng2021genetherapyrestores pages 4-6): Joanne Ng, Serena Barral, Carmen De La Fuente Barrigon, Gabriele Lignani, Fatma A. Erdem, Rebecca Wallings, Riccardo Privolizzi, Giada Rossignoli, Haya Alrashidi, Sonja Heasman, Esther Meyer, Adeline Ngoh, Simon Pope, Rajvinder Karda, Dany Perocheau, Julien Baruteau, Natalie Suff, Juan Antinao Diaz, Stephanie Schorge, Jane Vowles, Lucy R. Marshall, Sally A. Cowley, Sonja Sucic, Michael Freissmuth, John R. Counsell, Richard Wade-Martins, Simon J. R. Heales, Ahad A. Rahim, Maximilien Bencze, Simon N. Waddington, and Manju A. Kurian. Gene therapy restores dopamine transporter expression and ameliorates pathology in ipsc and mouse models of infantile parkinsonism. Science Translational Medicine, May 2021. URL: https://doi.org/10.1126/scitranslmed.aaw1564, doi:10.1126/scitranslmed.aaw1564. This article has 59 citations and is from a highest quality peer-reviewed journal.

  13. (ng2021genetherapyrestores pages 17-25): Joanne Ng, Serena Barral, Carmen De La Fuente Barrigon, Gabriele Lignani, Fatma A. Erdem, Rebecca Wallings, Riccardo Privolizzi, Giada Rossignoli, Haya Alrashidi, Sonja Heasman, Esther Meyer, Adeline Ngoh, Simon Pope, Rajvinder Karda, Dany Perocheau, Julien Baruteau, Natalie Suff, Juan Antinao Diaz, Stephanie Schorge, Jane Vowles, Lucy R. Marshall, Sally A. Cowley, Sonja Sucic, Michael Freissmuth, John R. Counsell, Richard Wade-Martins, Simon J. R. Heales, Ahad A. Rahim, Maximilien Bencze, Simon N. Waddington, and Manju A. Kurian. Gene therapy restores dopamine transporter expression and ameliorates pathology in ipsc and mouse models of infantile parkinsonism. Science Translational Medicine, May 2021. URL: https://doi.org/10.1126/scitranslmed.aaw1564, doi:10.1126/scitranslmed.aaw1564. This article has 59 citations and is from a highest quality peer-reviewed journal.

  14. (ng2021genetherapyrestores pages 6-8): Joanne Ng, Serena Barral, Carmen De La Fuente Barrigon, Gabriele Lignani, Fatma A. Erdem, Rebecca Wallings, Riccardo Privolizzi, Giada Rossignoli, Haya Alrashidi, Sonja Heasman, Esther Meyer, Adeline Ngoh, Simon Pope, Rajvinder Karda, Dany Perocheau, Julien Baruteau, Natalie Suff, Juan Antinao Diaz, Stephanie Schorge, Jane Vowles, Lucy R. Marshall, Sally A. Cowley, Sonja Sucic, Michael Freissmuth, John R. Counsell, Richard Wade-Martins, Simon J. R. Heales, Ahad A. Rahim, Maximilien Bencze, Simon N. Waddington, and Manju A. Kurian. Gene therapy restores dopamine transporter expression and ameliorates pathology in ipsc and mouse models of infantile parkinsonism. Science Translational Medicine, May 2021. URL: https://doi.org/10.1126/scitranslmed.aaw1564, doi:10.1126/scitranslmed.aaw1564. This article has 59 citations and is from a highest quality peer-reviewed journal.

  15. (aguilar2021psychomotorimpairmentsand pages 14-16): Jenny I Aguilar, Mary Hongying Cheng, Josep Font, Alexandra C Schwartz, Kaitlyn Ledwitch, Amanda Duran, Samuel J Mabry, Andrea N Belovich, Yanqi Zhu, Angela M Carter, Lei Shi, Manju A Kurian, Cristina Fenollar-Ferrer, Jens Meiler, Renae Monique Ryan, Hassane S Mchaourab, Ivet Bahar, Heinrich JG Matthies, and Aurelio Galli. Psychomotor impairments and therapeutic implications revealed by a mutation associated with infantile parkinsonism-dystonia. May 2021. URL: https://doi.org/10.7554/elife.68039, doi:10.7554/elife.68039. This article has 24 citations and is from a domain leading peer-reviewed journal.

  16. (ng2021genetherapyrestores pages 8-9): Joanne Ng, Serena Barral, Carmen De La Fuente Barrigon, Gabriele Lignani, Fatma A. Erdem, Rebecca Wallings, Riccardo Privolizzi, Giada Rossignoli, Haya Alrashidi, Sonja Heasman, Esther Meyer, Adeline Ngoh, Simon Pope, Rajvinder Karda, Dany Perocheau, Julien Baruteau, Natalie Suff, Juan Antinao Diaz, Stephanie Schorge, Jane Vowles, Lucy R. Marshall, Sally A. Cowley, Sonja Sucic, Michael Freissmuth, John R. Counsell, Richard Wade-Martins, Simon J. R. Heales, Ahad A. Rahim, Maximilien Bencze, Simon N. Waddington, and Manju A. Kurian. Gene therapy restores dopamine transporter expression and ameliorates pathology in ipsc and mouse models of infantile parkinsonism. Science Translational Medicine, May 2021. URL: https://doi.org/10.1126/scitranslmed.aaw1564, doi:10.1126/scitranslmed.aaw1564. This article has 59 citations and is from a highest quality peer-reviewed journal.

  17. (reid2023lossoffunctionvariantsin pages 2-4): Genomics England Research, Kimberley M Reid, D. Steel, Sanjana Nair, S. Bhate, L. Biassoni, S. Sudhakar, M. Heys, Elizabeth A Burke, E. Kamsteeg, Genomics England, Research Consortium, B. Hameed, M. Zech, N. Mencacci, Katy Barwick, M. Topf, and M. Kurian. Loss-of-function variants in drd1 in infantile parkinsonism-dystonia. Cells, 12:1046, Mar 2023. URL: https://doi.org/10.3390/cells12071046, doi:10.3390/cells12071046. This article has 15 citations.

  18. (reid2023lossoffunctionvariantsin pages 12-13): Genomics England Research, Kimberley M Reid, D. Steel, Sanjana Nair, S. Bhate, L. Biassoni, S. Sudhakar, M. Heys, Elizabeth A Burke, E. Kamsteeg, Genomics England, Research Consortium, B. Hameed, M. Zech, N. Mencacci, Katy Barwick, M. Topf, and M. Kurian. Loss-of-function variants in drd1 in infantile parkinsonism-dystonia. Cells, 12:1046, Mar 2023. URL: https://doi.org/10.3390/cells12071046, doi:10.3390/cells12071046. This article has 15 citations.

  19. (ng2023genetherapyfor pages 1-2): Joanne Ng, Serena Barral, Simon N. Waddington, and Manju A. Kurian. Gene therapy for dopamine dyshomeostasis: from parkinson's to primary neurotransmitter diseases. Movement Disorders, 38:924-936, May 2023. URL: https://doi.org/10.1002/mds.29416, doi:10.1002/mds.29416. This article has 23 citations and is from a highest quality peer-reviewed journal.

  20. (ng2023genetherapyfor pages 9-11): Joanne Ng, Serena Barral, Simon N. Waddington, and Manju A. Kurian. Gene therapy for dopamine dyshomeostasis: from parkinson's to primary neurotransmitter diseases. Movement Disorders, 38:924-936, May 2023. URL: https://doi.org/10.1002/mds.29416, doi:10.1002/mds.29416. This article has 23 citations and is from a highest quality peer-reviewed journal.

  21. (thalib2025acomparativeexploration pages 1-3): Husna Irfan Thalib, Rand Redwan Al Sari, Syeda Sobiah Imad, Sariya Khan, Shyma Haidar, Bayan Mohammed Khair Al Zoabi, Sahar Hamed Fadda, Samratul Fuadah, Hassan Abu Alwan, and Abdullah Alghobaishi. A comparative exploration of monoamine neurotransmitter transport disorders: mechanisms, clinical manifestations, and therapeutic approaches. Journal of Medicine and Life, 18:188-195, Mar 2025. URL: https://doi.org/10.25122/jml-2024-0398, doi:10.25122/jml-2024-0398. This article has 3 citations.

  22. (reid2023lossoffunctionvariantsin pages 8-10): Genomics England Research, Kimberley M Reid, D. Steel, Sanjana Nair, S. Bhate, L. Biassoni, S. Sudhakar, M. Heys, Elizabeth A Burke, E. Kamsteeg, Genomics England, Research Consortium, B. Hameed, M. Zech, N. Mencacci, Katy Barwick, M. Topf, and M. Kurian. Loss-of-function variants in drd1 in infantile parkinsonism-dystonia. Cells, 12:1046, Mar 2023. URL: https://doi.org/10.3390/cells12071046, doi:10.3390/cells12071046. This article has 15 citations.

  23. (kaasalainen2024novelslc18a2variant pages 3-4): Sakari Kaasalainen, Harri Arikka, Mika H. Martikainen, and Valtteri Kaasinen. Novel slc18a2 variant in infantile dystonia-parkinsonism type 2. Case Reports in Neurological Medicine, Apr 2024. URL: https://doi.org/10.1155/2024/4767647, doi:10.1155/2024/4767647. This article has 3 citations and is from a peer-reviewed journal.

Artifacts